argenx NV ADR (ARGX)vsWheaton Precious Metals Corp (WPM)
ARGX
argenx NV ADR
$782.17
-0.65%
HEALTHCARE · Cap: $49.20B
WPM
Wheaton Precious Metals Corp
$138.85
+5.54%
BASIC MATERIALS · Cap: $59.74B
Smart Verdict
WallStSmart Research — data-driven comparison
argenx NV ADR generates 105% more annual revenue ($4.74B vs $2.31B). WPM leads profitability with a 63.6% profit margin vs 31.4%. WPM appears more attractively valued with a PEG of 0.43. WPM earns a higher WallStSmart Score of 76/100 (B+).
ARGX
Strong Buy75
out of 100
Grade: B
WPM
Strong Buy76
out of 100
Grade: B+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+64.4%
Fair Value
$2344.11
Current Price
$782.17
$1561.94 discount
Intrinsic value data unavailable for WPM.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Keeps 31 of every $100 in revenue as profit
Strong operational efficiency at 30.0%
Revenue surging 62.6% year-over-year
Earnings expanding 114.0% YoY
Every $100 of equity generates 20 in profit
Growing faster than its price suggests
Keeps 64 of every $100 in revenue as profit
Strong operational efficiency at 75.2%
Revenue surging 127.2% year-over-year
Earnings expanding 533.0% YoY
Large-cap with strong market position
Areas to Watch
Premium valuation, high expectations priced in
Weak financial health signals
Trading at 165.4x book value
Premium valuation, high expectations priced in
Comparative Analysis Report
WallStSmart ResearchBull Case : ARGX
The strongest argument for ARGX centers on Profit Margin, Operating Margin, Revenue Growth. Profitability is solid with margins at 31.4% and operating margin at 30.0%. Revenue growth of 62.6% demonstrates continued momentum.
Bull Case : WPM
The strongest argument for WPM centers on PEG Ratio, Profit Margin, Operating Margin. Profitability is solid with margins at 63.6% and operating margin at 75.2%. Revenue growth of 127.2% demonstrates continued momentum.
Bear Case : ARGX
The primary concerns for ARGX are P/E Ratio, Piotroski F-Score, Price/Book.
Bear Case : WPM
The primary concerns for WPM are P/E Ratio. A P/E of 40.6x leaves little room for execution misses.
Key Dynamics to Monitor
WPM carries more volatility with a beta of 1.18 — expect wider price swings.
WPM is growing revenue faster at 127.2% — sustainability is the question.
ARGX generates stronger free cash flow (407M), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
WPM scores higher overall (76/100 vs 75/100), backed by strong 63.6% margins and 127.2% revenue growth. ARGX offers better value entry with a 64.4% margin of safety. Both earn "Strong Buy" and "Strong Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
argenx NV ADR
HEALTHCARE · BIOTECHNOLOGY · USA
argenx SE, a clinical-phase biotechnology company, focuses on the development of antibody-based therapies for the treatment of autoimmune diseases, hematology and cancer. The company is headquartered in Breda, the Netherlands.
Wheaton Precious Metals Corp
BASIC MATERIALS · GOLD · USA
Wheaton Precious Metals Corp. The company is headquartered in Vancouver, Canada.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?